角膜基质内注射伏立康唑治疗真菌性角膜炎的疗效及安全性分析  

Effect and safety analysis of voriconazole injection into corneal stroma for fungal keratitis

作　　者：陈敏 CHEN Min(Chongqing Dianjiang People’s Hospital,Chongqing 408300,China)

机构地区：[1]重庆市垫江县人民医院,重庆408300

出　　处：《当代医药论丛》2022年第13期106-108,共3页

摘　　要：目的:研究用角膜基质内注射伏立康唑疗法治疗真菌性角膜炎的临床疗效及安全性。方法:选择2017年7月至2020年11月期间重庆市垫江县人民医院收治的真菌性角膜炎患者35例为研究对象。按照随机数表法将其分为伏立康唑组(n=18)和常规治疗组(n=17)。为常规治疗组患者采用那他霉素滴眼疗法进行治疗,在此基础上为伏立康唑组患者采用角膜基质内注射伏立康唑疗法进行治疗。然后比较两组患者的临床疗效。结果:伏立康唑组患者治疗的总有效率高于常规治疗组患者,差异有统计学意义(P<0.05)。治疗后,伏立康唑组患者眼部异物感、前房积脓、角膜溃疡、畏光流泪症状消失的时间均短于常规治疗组患者,差异有统计学意义(P<0.05)。治疗3 d后、治疗7 d后、治疗14 d后、治疗28 d后,伏立康唑组患者角膜炎严重程度的评分均低于常规治疗组患者,差异有统计学意义(P<0.05)。治疗后,两组患者不良反应的发生率相比,差异无统计学意义(P>0.05)。结论:用角膜基质内注射伏立康唑疗法治疗真菌性角膜炎可取得较好的临床疗效,能够快速缓解患者的临床症状,减轻其角膜的炎症反应,且安全性较高。Objective:To study the clinical efficacy and safety of voriconazole injection into the stroma of cornea in the treatment of fungal keratitis.Methods:A total of 35 patients with fungal keratitis admitted to People’s Hospital of Dianjiang County,Chongqing from July 2017 to November 2020 were selected as the subjects.They were divided into voriconazole group(n=18)and conventional treatment group(n=17)according to random number table method.Patients in the conventional treatment group were treated with nathamycin eye drops,and patients in the voriconazole group were treated with intrastromal injection of voriconazole.Then the clinical efficacy of the two groups was compared.Results:The total effective rate of voriconazole group was higher than that of conventional treatment group,the difference was statistically significant(P<0.05).After treatment,the time of disappearance of ocular foreign body sensation,anterior atrial pus,corneal ulcer and photophobia in voriconazole group was shorter than that in conventional treatment group,with statistical significance(P<0.05).After 3 d of treatment,7 d of treatment,14 d of treatment and 28 d of treatment,the keratitis severity score of voriconazole group was lower than that of conventional treatment group,the difference was statistically significant(P<0.05).After treatment,there was no significant difference in the incidence of adverse reactions between 2 groups(P>0.05).Conclusion:The treatment of fungal keratitis with voriconazole injection in the stroma of cornea can achieve good clinical efficacy,can quickly relieve the clinical symptoms of patients,reduce the corneal inflammation,and high safety.

关 键 词：角膜基质内注射 伏立康唑 真菌性角膜炎 

分 类 号：R772.21[医药卫生—眼科]